Nationwide non-profit fighting cancer with research, education, patient support
A roundup of recent cancer breakthroughs highlights new immunotherapies, targeted drugs and surgical-sparing treatments. The Independent reports on Scolyer’s pioneering work and a landmark NICE decision; The Guardian covers durvalumab’s promise in bladder cancer; Business Insider UK and Reuters summarize ASCO findings on pancreatic and colon cancers, among others.
The FDA has approved bemotrizinol (BEMT) for over‑the‑counter sunscreens, marking a modernization in U.S. UV protection. The ingredient absorbs both UVA and UVB rays, is photostable, and will debut as Parsol Shield before broader market adoption after an 18‑month exclusivity period. Industry and dermatology experts say the move could improve protection and user experience, though rollout and formulation timelines remain.
Five or more sunburns raise melanoma risk by up to 80%, with age and burn severity shaping outcomes. Experts urge daily sunscreen and preventive care as cases rise across the United States.
Vivani Medical and Novo Nordisk are exploring a long-acting semaglutide implant to maintain weight loss, potentially replacing frequent injections. The device aims to release medicine steadily for months, pending clinical and regulatory validation.
The SNAP program has faced a historic remolding, with participation falling significantly since the 2025 cost-shift law. States are adapting with tighter eligibility and higher administrative hurdles, while food banks brace for higher demand amid rising prices.Mayors urge reversal of cuts as hunger risk grows.
Sims, eight years after a melanoma diagnosis, is warning that tanning is surging again among young people online. Experts say tanning beds dramatically raise melanoma risk, with DNA mutations more likely in users. Reports show 100,000+ melanomas expected in 2026; influencers promote tanning, while dermatologists stress there is no safe tan.